Análisis Argos
RDY
RDYSin veredicto
Dr. Reddy's Laboratories Limited · Healthcare
US$ 11.73
precio al 2026-07-28
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
72/100
Sin veredicto
LA RESPUESTA
No tenemos un veredicto de valuación confiable acá: su flujo de caja no permite una estimación sólida. Mirá su calidad y su salud para formarte una idea — preferimos eso a inventarte un número.
VALOR6/6FUTURO3/6PASADO2/6SALUD5/6DIVIDENDO6/6
El Iris de calidad
VALOR6/6FUTURO3/6PASADO2/6SALUD5/6DIVIDENDO6/6
ValorCotiza por debajo de su valor justo
FuturoCrecimiento moderado
PasadoHistorial aceptable
SaludBalance fuerte, deuda controlada
DividendoDevuelve capital al accionista
Score Argos72de 100Sin veredicto
Ingresos▲9%
US$ 353.5 B
Margen operativo▼38%
13.8%
Flujo de caja libre▲167%
US$ 32.1 B
Deuda neta
US$ 60.8 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 9.8B
P/E0.2x
EV/EBITDA1x
FCF yield328.6%
ROIC8.8%
Margen operativo13.8%
Crecim. ingresos+8.6%/año
Piotroski F4/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

seekingalpha.com · 10 jul
Dr. Reddy's Laboratories Limited (RDY) Discusses Manufacturing Issue and Process Review for Semaglutide Transcript
Dr. Reddy's Laboratories Limited (RDY) Discusses Manufacturing Issue and Process Review for Semaglutide Transcript
reuters.com · 9 jul
India's Torrent Pharma recalls select semaglutide pens after Dr. Reddy's notice
Torrent Pharmaceuticals ​said ‌on Thursday it ​was ​voluntarily recalling ⁠select ​batches ​of its Semalix semaglutide ​injection ​disposable pens ‌after ⁠a product recall notification ​from ​its ⁠manufacturer ​Dr. ​Reddy's ⁠Laboratories.
businesswire.com · 26 jun
Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #AmericanDepositaryReceipts--Dr. Reddy's Laboratories Limited announces filing of Annual Report on Form 20-F.
businesswire.com · 13 jun
Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Bosulif--Dr. Reddy's Laboratories Ltd. announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif® in the United States.
prnewswire.com · 29 may
NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, May 29, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor.
feeds.benzinga.com · 16 may
Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push
Dr. Reddy's launched generic Semaglutide Injection in Canada, expanding its GLP-1 portfolio and strengthening its affordable diabetes treatment presence.
businesswire.com · 16 may
Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $RDY #DrReddy--Dr. Reddy's Laboratories Ltd. a global pharmaceutical company, today announced the launch of its generic Semaglutide Injection in Canada.
marketbeat.com · 14 may
Dr. Reddy's Laboratories Q4 Earnings Call Highlights
Dr. Reddy's Laboratories NYSE: RDY reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide sales and several one-time charges during the fourth quarter.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.